CL2017002826A1 - Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015) - Google Patents

Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015)

Info

Publication number
CL2017002826A1
CL2017002826A1 CL2017002826A CL2017002826A CL2017002826A1 CL 2017002826 A1 CL2017002826 A1 CL 2017002826A1 CL 2017002826 A CL2017002826 A CL 2017002826A CL 2017002826 A CL2017002826 A CL 2017002826A CL 2017002826 A1 CL2017002826 A1 CL 2017002826A1
Authority
CL
Chile
Prior art keywords
composition
treat
risk
reduce
gastrointestinal motility
Prior art date
Application number
CL2017002826A
Other languages
English (en)
Inventor
Eamonn Connolly
John Bienenstock
Wolfgang Kunze
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49115523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002826(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of CL2017002826A1 publication Critical patent/CL2017002826A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/10—Segmentation; Edge detection
    • G06T7/13—Edge detection
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30092—Stomach; Gastric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Quality & Reliability (AREA)

Abstract

<p>UNA CEPA BACTERIANA QUE REDUCE LA SEÑALIZACIÓN DEL DOLOR MEDIANTE LA REDUCCIÓN DEL DISPARO NERVIOSO AFERENTE MESENTÉRICO Y ALTERE LA MOTILIDAD GASTROINTESTINAL EN UN SUJETO, DONDE DICHA CEPA SE SELECCIONA DE LACTOHACILLUS GASSERI 345A (LG345A) DEPOSITADA EN DSMZ BAJO EL NO. DE ACCESO DSM-27123, LACTOBACILLUS GASSERI 621A (LG621A) DEPOSITADA EN DSMZ BAJO EL NO. DE ACCESO DSM-27126 O LACTOBACILLUS REUTEN DEPOSITADA EN DSMZ BAJO EL NO. DE ACCESO DSM 17938. UNA COMPOSICIÓN QUE COMPRENDE UNA DE DICHAS CEPAS BACTERIANAS. USO DE DICHA COMPOSICIÓN PARA TRATAR LA CONSTIPACIÓN O CÓLICOS O REDUCIR EL RIESGO DE DESARROLLAR CONSTIPACIÓN O CÓLICOS EN UN SUJETO. USO DE DICHA COMPOSICIÓN PARA TRATAR O REDUCIR EL RIESGO DE DESARROLLAR SÍNDROME DEL INTESTINO IRRITABLE EN DICHO SUJETO.</p>
CL2017002826A 2012-09-03 2017-11-08 Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015) CL2017002826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261696277P 2012-09-03 2012-09-03

Publications (1)

Publication Number Publication Date
CL2017002826A1 true CL2017002826A1 (es) 2018-04-06

Family

ID=49115523

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000490A CL2015000490A1 (es) 2012-09-03 2015-02-27 Método para la selección de agentes para el tratamiento de un trastorno de la motilidad intestinal; cepa bacteriana seleccionada por el método; y método de tratamiento.
CL2017002826A CL2017002826A1 (es) 2012-09-03 2017-11-08 Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015000490A CL2015000490A1 (es) 2012-09-03 2015-02-27 Método para la selección de agentes para el tratamiento de un trastorno de la motilidad intestinal; cepa bacteriana seleccionada por el método; y método de tratamiento.

Country Status (27)

Country Link
US (5) US9555065B2 (es)
EP (2) EP3369808A1 (es)
JP (3) JP6259458B2 (es)
KR (1) KR102293438B1 (es)
CN (4) CN108904545A (es)
AU (1) AU2013308299B2 (es)
CA (2) CA2883440A1 (es)
CL (2) CL2015000490A1 (es)
CO (1) CO7350654A2 (es)
DK (1) DK2893045T3 (es)
ES (1) ES2681974T3 (es)
GE (1) GEP201706775B (es)
HK (1) HK1258778A1 (es)
HR (1) HRP20181033T1 (es)
IL (2) IL237397B (es)
IN (1) IN2015DN01572A (es)
LT (1) LT2893045T (es)
MX (2) MX362495B (es)
MY (2) MY182358A (es)
NZ (1) NZ705358A (es)
PH (1) PH12015500452B1 (es)
RU (1) RU2701348C2 (es)
SG (3) SG10202101556WA (es)
SI (1) SI2893045T1 (es)
UA (2) UA118339C2 (es)
WO (1) WO2014033330A1 (es)
ZA (1) ZA201501472B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CN108094541A (zh) * 2018-01-11 2018-06-01 黑龙江完达山林海液奶有限公司 一种具有保健益生功能的风味发酵乳及其制备方法
US11911424B2 (en) * 2018-07-24 2024-02-27 Biogaia Ab Selection and use of melatonin supporting bacteria to reduce infantile colic
EP3980288B1 (en) * 2019-06-05 2025-02-26 AVL Mobility Technologies, Inc. Vehicle axle assembly
US12263752B2 (en) 2019-06-05 2025-04-01 Avl Mobility Technologies, Inc. Vehicle frame and power supply assembly and related systems and methods
CN113939417A (zh) 2019-06-05 2022-01-14 Avl动力工程公司 车辆框架组件和电源托盘
CN110186922B (zh) * 2019-06-25 2021-07-23 西安交通大学医学院第一附属医院 一种监测结肠移行性复合运动的实验装置及方法
US11843097B2 (en) 2019-09-10 2023-12-12 Avl Powertrain Engineering, Inc. Power supply control systems and methods
CN112710823B (zh) * 2020-12-17 2024-03-29 中国科学院深圳先进技术研究院 一种肠移行性复合运动的离体检测系统及其应用
CN114342878B (zh) * 2022-01-10 2022-09-30 南京鼓楼医院 一种慢传输型便秘动物模型的建立方法
CN117384804A (zh) * 2023-12-12 2024-01-12 北京三元食品股份有限公司 格氏乳杆菌b1-26及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438989A (en) * 1990-08-10 1995-08-08 Hochman; Darryl Solid tumor, cortical function, and nerve tissue imaging methods and device
ID28510A (id) * 1998-08-21 2001-05-31 Novartis Ag Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
EP1196164A2 (en) * 1999-07-06 2002-04-17 Enpharma L.P. Methods and compositions for regulating gut motility and food intake
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
CN1663573B (zh) * 2004-03-04 2010-04-28 青岛东海药业有限公司 一种稳定安全的微生态制剂及其制备方法和用途
US20090233888A1 (en) * 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
JP5036020B2 (ja) * 2005-11-30 2012-09-26 雪印メグミルク株式会社 腎周囲脂肪蓄積抑制剤
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
JP5019563B2 (ja) * 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101801200B (zh) * 2007-09-17 2014-10-29 康奈尔大学 用于预防或治疗胃肠病症的支链脂肪酸
EP2459202A1 (en) * 2009-07-31 2012-06-06 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
US20110110905A1 (en) * 2009-11-06 2011-05-12 Ritchie Jennifer A Infant Colic Supplement
WO2011148219A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
US20120034198A1 (en) * 2010-08-04 2012-02-09 Microbios, Inc. Carriers for storage and delivery of biologics
CN102304489B (zh) * 2011-09-23 2013-06-12 北京龙科方舟生物工程技术有限公司 一株罗伊氏乳杆菌及其应用

Also Published As

Publication number Publication date
RU2701348C2 (ru) 2019-09-26
IL259652B (en) 2020-03-31
US9816150B2 (en) 2017-11-14
CN108753645B (zh) 2019-10-22
PH12015500452A1 (en) 2015-04-20
JP6476328B2 (ja) 2019-02-27
JP2015529329A (ja) 2015-10-05
ZA201501472B (en) 2016-06-29
AU2013308299B2 (en) 2019-04-18
US10174388B2 (en) 2019-01-08
UA126374C2 (uk) 2022-09-28
CN109966511A (zh) 2019-07-05
SG10202101556WA (en) 2021-03-30
CN108904545A (zh) 2018-11-30
CL2015000490A1 (es) 2015-05-29
DK2893045T3 (en) 2018-07-30
HRP20181033T1 (hr) 2018-08-24
EP2893045A1 (en) 2015-07-15
IL237397A0 (en) 2015-04-30
IL259652A (en) 2018-07-31
HK1258778A1 (zh) 2019-11-22
ES2681974T3 (es) 2018-09-17
SG10201608055XA (en) 2016-11-29
US20180023150A1 (en) 2018-01-25
JP2018090616A (ja) 2018-06-14
MX2015002792A (es) 2015-05-07
CN104918640A (zh) 2015-09-16
EP3369808A1 (en) 2018-09-05
US20170114422A1 (en) 2017-04-27
CN104918640B (zh) 2019-03-19
IL237397B (en) 2018-10-31
US20150231186A1 (en) 2015-08-20
JP6259458B2 (ja) 2018-01-10
US20190112676A1 (en) 2019-04-18
AU2013308299A1 (en) 2015-03-26
HK1211848A1 (en) 2016-06-03
MY182358A (en) 2021-01-20
EP2893045B1 (en) 2018-05-16
WO2014033330A1 (en) 2014-03-06
SI2893045T1 (en) 2018-08-31
NZ705358A (en) 2018-09-28
CA2883440A1 (en) 2014-03-06
MX2018013097A (es) 2020-09-02
UA118339C2 (uk) 2019-01-10
SG11201501297TA (en) 2015-03-30
KR102293438B1 (ko) 2021-08-25
JP2018029588A (ja) 2018-03-01
KR20150048201A (ko) 2015-05-06
US9555065B2 (en) 2017-01-31
GEP201706775B (en) 2017-11-27
RU2015112102A (ru) 2016-10-20
LT2893045T (lt) 2018-07-25
IN2015DN01572A (es) 2015-07-03
CO7350654A2 (es) 2015-08-10
CA3268968A1 (en) 2025-11-29
PH12015500452B1 (en) 2023-01-20
MX362495B (es) 2019-01-21
CN108753645A (zh) 2018-11-06
US20220306984A1 (en) 2022-09-29
JP6322326B2 (ja) 2018-05-09
MY195532A (en) 2023-01-31
HK1258774A1 (zh) 2019-11-22

Similar Documents

Publication Publication Date Title
ES2561253T3 (es) Bacterias probióticas que tienen actividad antioxidante y uso de las mismas
ES2550059T3 (es) Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales
BR112015025256A8 (pt) Cepas probióticas para uso no tratamento ou prevenção da osteoporose
MX2010001692A (es) Ciertas entidades quimicas, composiciones y metodos.
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
MX2012002402A (es) Bifidobacterium longum y trastornos gastrointestinales funcionales.
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2017005497A (es) Uso de l. reuteri para la recuperacion de la disbiosis de microbiota en los primeros años de vida.
EP4272815A3 (en) New medical use of probiotics
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
MX2021009001A (es) Composiciones microbianas para alimentacion directa y sus metodos de uso.
MX380345B (es) Cepas de salmonella para uso en el tratamiento y/o prevencion de cancer.
MY155299A (en) Oral dosage composition
CL2019001938A1 (es) Composiciones probióticas y usos de las mismas.
EA201690147A1 (ru) Пероральные композиции
MX378890B (es) Bifidobacterium longum ncimb 41715 para usarse en el tratamiento de obesidad y trastornos metabólicos asociados.
MY171618A (en) Strain of lactobacillus as probiotic
BR112017023636A2 (pt) suplemento dietético
CL2011002597A1 (es) Compuestos derivados de rifamicina; procedimiento de preparacion; composicion farmaceutica; su uso para tratar, prevenir o aliviar sobrecrecimiento bacteriano en trastornos intestinales tales como sindrome de colon irritable, diarrea del viajante, enfermedad de crohn, encefalopatia hepatica y enteritis.
EA201291440A1 (ru) Пробиотические штаммы для применения при повышении трансэпителиального сопротивления
CL2011001937A1 (es) Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad.
MX388656B (es) Composiciones para el cuidado bucal y metodos de uso
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
MX2021012676A (es) Composiciones probioticas y usos de las mismas.
PL3741218T3 (pl) Szczep lactobacillus salivarus oraz jego zastosowanie w zapobieganiu biegunce poodsadzeniowej u prosiąt i w jej leczeniu